Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-01-16

Clinical Trial Update: LUCAS (Lucentis Compared to Avastin Study) [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing ranibizumab (Lucentis) to bevacizumab (Avastin) for exudative age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avastin (bevacizumab)
  • Lucentis (ranibizumab)

Snippet

Sponsor: Oslo University Hospital | Conditions: Exudative Age-related Macular Degeneration | Phase 4 | Status: COMPLETED